Can-Fite BioPharma (CANF) said Tuesday that the US Food and Drug Administration has approved the compassionate use treatment with anti-cancer drug Namodenoson for a pancreatic cancer patient in the US.
The clinical-stage company said it is currently evaluating Namodenoson in a late-stage clinical trial for advanced liver cancer, while it is also testing the drug in a phase 2a pancreatic cancer clinical trial in Israel.
The FDA has also granted orphan drug designation to Namodenoson, the company said.
Shares of the company rose 12% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。